<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Drug Policy</journal-id><journal-id journal-id-type="iso-abbrev">Int J Drug Policy</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The International journal on drug policy</journal-title></journal-title-group><issn pub-type="ppub">0955-3959</issn><issn pub-type="epub">1873-4758</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12045481</article-id><article-id pub-id-type="pmcid-ver">PMC12045481.1</article-id><article-id pub-id-type="pmcaid">12045481</article-id><article-id pub-id-type="pmcaiid">12045481</article-id><article-id pub-id-type="manuscript-id">NIHMS2073481</article-id><article-id pub-id-type="pmid">40020306</article-id><article-id pub-id-type="doi">10.1016/j.drugpo.2025.104748</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2073481</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2073481</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ivasiy</surname><given-names initials="R">Roman</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Madden</surname><given-names initials="LM">Lynn M.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="KA">Kimberly A.</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Machavariani</surname><given-names initials="E">Eteri</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="B">Bachar</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oliveros</surname><given-names initials="D">David</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tan</surname><given-names initials="J">Jiale</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kil</surname><given-names initials="N">Natalie</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Altice</surname><given-names initials="FL">Frederick L.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref><xref rid="A7" ref-type="aff">g</xref><xref rid="A8" ref-type="aff">h</xref></contrib></contrib-group><aff id="A1"><label>a</label>Yale School of Medicine, Section of Infectious Diseases, New Haven, CT, United States</aff><aff id="A2"><label>b</label>Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States</aff><aff id="A3"><label>c</label>APT Foundation, New Haven, CT, United States</aff><aff id="A4"><label>d</label>College of Behavioral and Community Science, Department of Mental Health Law and Policy, University of South Florida, Tampa, FL, United States</aff><aff id="A5"><label>e</label>Yale School of Medicine, New Haven, CT, United States</aff><aff id="A6"><label>f</label>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States</aff><aff id="A7"><label>g</label>Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, United States</aff><aff id="A8"><label>h</label>Yale School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, CT, United States</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author at: 135 College Street, Suite 323, New Haven, CT 06510-2283, United States. <email>roman.ivasiy@yale.edu</email> (R. Ivasiy).</corresp><fn fn-type="COI-statement" id="FN2"><p id="P34">Declaration of competing interest</p><p id="P35">None.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>2</month><year>2025</year></pub-date><volume>138</volume><issue-id pub-id-type="pmc-issue-id">487698</issue-id><fpage>104748</fpage><lpage>104748</lpage><pub-history><event event-type="nihms-submitted"><date><day>26</day><month>04</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-02 16:25:14.117"><day>02</day><month>05</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2073481.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and aims:</title><p id="P1">Maintenance on medications for opioid use disorder, particularly buprenorphine, is critical for reducing overdose risk and improving health outcomes in the United States. This study evaluates retention and dropout probabilities between sublingual buprenorphine (SL-BUP) and extended-release buprenorphine (XR-BUP) among commercially-insured individuals with opioid use disorder (OUD).</p></sec><sec id="S2"><title>Design and setting:</title><p id="P2">A retrospective cohort study using Meretive<sup>&#8482;</sup> Markeskan<sup>&#174;</sup> claims data from 2019 to 2020. A multi-state Markov model assessed transitions between treatment states over 12 months.</p></sec><sec id="S3"><title>Participants:</title><p id="P3">The study included 58,933 individuals aged 18&#8211;64 years with OUD, initiating SL-BUP (<italic toggle="yes">n</italic> = 57,520) or XR-BUP (<italic toggle="yes">n</italic> = 1,413). XR-BUP patients were divided into XR-BUP only (<italic toggle="yes">n</italic> = 684; 49 %) and XR-BUP with supplemental SL-BUP (XR-BUP+sSL; <italic toggle="yes">n</italic> = 729; 51 %).</p></sec><sec id="S4"><title>Measurements:</title><p id="P4">Primary outcomes included probabilities of remaining in treatment or transitioning between states at 1, 3, 6, and 12 months. The impact of dosage and days of supply on retention was also examined.</p></sec><sec id="S5"><title>Results:</title><p id="P5">The probability of permanent treatment dropout at 6 months was similar for SL-BUP (38.59 %, 95 % CI: 37.9 %-39.4 %) and XR-BUP (41.3 % 95 %CI: 36.8 %-46.1 %), yet the probability of remaining in treatment was significantly higher for SL-BUP than XR-BUP (49.5 %; 95 %CI: 48.8 %-50.1 % vs. 13.5 % 95 % CI: 10.5 %-16.5 %). The high proportion of individuals initially prescribed XR-BUP later transitioned to SL-BUP. Higher doses and longer days supplied of SL-BUP reduced dropout rates. Among patients receiving &#8805;16 mg/day and &#8805;28 days, dropout probabilities were 5.7 % (95 % CI: 5.4 %-6.0 %) at 1 month, 15.4 % (95 % CI: 14.8 %-16.2 %) at 3 months, 28.0 % (95 % CI: 26.9 %-29.2 %) at 6 months, and 47.8 % (95 %CI: 45.2 %-49.5 %) at 12 months. In contrast, patients prescribed &lt;16 mg/day and &lt;28 days had a 46.3 % (95 %CI: 45.0 %-47.6 %) dropout rate by 6 months.</p></sec><sec id="S6"><title>Conclusion:</title><p id="P6">SL-BUP demonstrates higher retention rates and lower dropout compared to XR-BUP in real-world settings. Optimizing SL-BUP dosing and providing extended supplies can improve retention and reduce treatment discontinuation.</p></sec></abstract><kwd-group><kwd>Opioid use disorder</kwd><kwd>Buprenorphine</kwd><kwd>Extended-release buprenorphine</kwd><kwd>Medications for opioid use disorder (MOUD)</kwd><kwd>Communicable comorbidities</kwd><kwd>HIV</kwd><kwd>HCV</kwd><kwd>Treatment initiation</kwd><kwd>Treatment retention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>